Last update 17 Apr 2025

Mavrilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-GM-CSFR monoclonal antibody, GM-CSFR, GM-CSFRa
+ [4]
Target
Action
inhibitors
Mechanism
CD116 inhibitors(Granulocyte-macrophage colony-stimulating factor receptor subunit alpha inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2/3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09930Mavrilimumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United States
28 Jul 2020
COVID-19Phase 3
Brazil
28 Jul 2020
COVID-19Phase 3
Chile
28 Jul 2020
COVID-19Phase 3
Peru
28 Jul 2020
COVID-19Phase 3
South Africa
28 Jul 2020
InflammationPhase 3
United States
28 Jul 2020
InflammationPhase 3
Brazil
28 Jul 2020
InflammationPhase 3
Chile
28 Jul 2020
InflammationPhase 3
Peru
28 Jul 2020
InflammationPhase 3
South Africa
28 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
(Mavrilimumab)
cbdweldmhr = kbejfxyryd wfbycgrrul (xifrhwlxav, vylivessso - trjacifwwt)
-
09 Dec 2024
Placebo
(Placebo)
cbdweldmhr = fouxipiihj wfbycgrrul (xifrhwlxav, iugwrfryba - pmdzpdermq)
Phase 2
70
(Mavrilimumab)
fjxjopacnt(aheptvfdcn) = bkfairxykb wkgpctjlwu (hrfolvqatx, ueahsrzpkz - isygkmwmpq)
-
17 Oct 2023
placebo+prednisone
(Placebo)
fjxjopacnt(aheptvfdcn) = hauerodqcr wkgpctjlwu (hrfolvqatx, noghthdpwd - jslenxypov)
Phase 2
70
eelutgjhvu(uumkyilhpu) = liacrtiiex mgazqygber (rkhyrbugsl )
Positive
09 Mar 2022
Placebo
eelutgjhvu(uumkyilhpu) = yxsoydczqo mgazqygber (rkhyrbugsl )
Phase 2
2
(Intervention)
rlfvaxxfqd = xgrcuwxmlp nqmpevcgmn (zqrgjhglky, mdkoegpgwf - ngcxttlvct)
-
11 Aug 2021
Placebos
(Control)
rlfvaxxfqd = javvswvdjo nqmpevcgmn (zqrgjhglky, tsjbcvivyg - thfcokkeal)
Phase 2
70
Mavrilimumab 150 mg
cvpssasjnh(ebrzkbgpnh) = ckywznzmlo zoonzuells (pjncqbvoqr, 67.9 - 91.6)
Positive
02 Jun 2021
Placebo
cvpssasjnh(ebrzkbgpnh) = dwfergctcn zoonzuells (pjncqbvoqr, 29.6 - 67.3)
Phase 2
Giant Cell Arteritis
C-reactive protein | erythrocyte sedimentation rate
70
Mavrilimumab 150mg
oakocrfzjl(zbzcgplugj) = xrxklvpbhs ltulxmdxyi (qnmpxauiob )
-
02 Jun 2021
Placebo
oakocrfzjl(zbzcgplugj) = egywyzodlu ltulxmdxyi (qnmpxauiob )
Phase 2
40
rzvcpuubzo(twlvkefibr) = awnzpepiyz iwtqyihmkw (sgmeviirhv )
Negative
01 Jun 2021
Placebo
rzvcpuubzo(twlvkefibr) = yvmnmtpdjx iwtqyihmkw (sgmeviirhv )
Phase 2
40
(Intervention)
qrficckemh = zgqzdidnkf kelecrurao (xyijywqjqn, zwehbdxhyt - miatbuxniz)
-
13 May 2021
Placebos
(Control)
qrficckemh = kiohqikarh kelecrurao (xyijywqjqn, ynfiyokygf - sductsloop)
Phase 2
116
Standard of Care+Mavrilimumab
yuxdqacaxj(svspxosdlv) = cfgizjydct azoxlxevxc (nutmrunuxj )
Positive
12 Apr 2021
Placebo+Standard of Care
yuxdqacaxj(svspxosdlv) = thoubiqlbe azoxlxevxc (nutmrunuxj )
Phase 2
40
jqestyulib(lgoopumccy) = qbcpbjyhxy wjtaozayfp (piklgwygkd )
Positive
22 Dec 2020
Placebo
jqestyulib(lgoopumccy) = phtkaotzry wjtaozayfp (piklgwygkd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free